Ubrogepant
- Generic Name
- Ubrogepant
- Brand Names
- Ubrelvy
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26F3N5O3
- CAS Number
- 1374248-77-7
- Unique Ingredient Identifier
- AD0O8X2QJR
- Background
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor antagonists, belonging to a class of med...
- Indication
Ubrogepant is indicated for the acute treatment of migraine with or without aura in adults.
- Associated Conditions
- Migraine With Aura, Migraine Without Aura
- Associated Therapies
- -
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 40
- Registration Number
- NCT06578585
- Locations
- 🇺🇸
Clinical Neuroscience Solutions, Orlando, Florida, United States
🇺🇸NeuroTrials Research, Atlanta, Georgia, United States
🇺🇸Future Search Trials, Austin, Texas, United States
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 450
- Registration Number
- NCT06417775
- Locations
- 🇺🇸
New England Institute for Clinical Research /ID# 264019, Stamford, Connecticut, United States
🇺🇸Central Research Associates /ID# 260161, Birmingham, Alabama, United States
🇺🇸MD First Research - Chandler /ID# 262564, Chandler, Arizona, United States
Migraine Medication Effects on Urinary Symptoms
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT06212661
- Locations
- 🇺🇸
Cleveland Clinic, Main Campus, Cleveland, Ohio, United States
Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05892757
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, LLC /ID# 255452, Springfield, Missouri, United States
🇺🇸Icon /Id# 257525, Salt Lake City, Utah, United States
🇺🇸Icon /Id# 257524, San Antonio, Texas, United States
Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 20
- Registration Number
- NCT05654298
- Locations
- 🇧🇪
Center for Clinical Pharmacology, Leuven, Belgium
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 263
- Registration Number
- NCT05264129
- Locations
- 🇺🇸
Advanced Research Institute - Ridgeline /ID# 242662, Ogden, Utah, United States
🇺🇸Clinvest Research LLC /ID# 242597, Springfield, Missouri, United States
🇺🇸Aventiv Research Columbus /ID# 242462, Columbus, Ohio, United States
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1200
- Registration Number
- NCT05127954
- Locations
- 🇺🇸
Pediatrix Medical Group of Florida /ID# 233336, Winter Park, Florida, United States
🇺🇸Centricity Research Columbus /ID# 238832, Columbus, Ohio, United States
🇺🇸Houston Clinical Research Associates /ID# 246522, Houston, Texas, United States
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1059
- Registration Number
- NCT05125302
- Locations
- 🇺🇸
Encore Medical Research /ID# 245682, Hollywood, Florida, United States
🇺🇸Advanced Research Institute of Miami /ID# 230292, Homestead, Florida, United States
🇺🇸Auzmer Research /ID# 239251, Lakeland, Florida, United States
Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 26
- Registration Number
- NCT04818515
- Locations
- 🇺🇸
PPD Clinical Research Unit /ID# 227676, Orlando, Florida, United States
🇺🇸Bio-Kinetic Clinical Applications, LLC /ID# 227675, Springfield, Missouri, United States
🇺🇸Spaulding Clinical Research LLC /ID# 229505, West Bend, Wisconsin, United States
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Allergan
- Target Recruit Count
- 40
- Registration Number
- NCT04179474
- Locations
- 🇺🇸
Spaulding, West Bend, Wisconsin, United States
🇺🇸QPS, Springfield, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.